Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026
PR Newswire•19/11/2026•13:35 ET
0
Key Highlights
- ➤Lecanemab reduced CDR-SB decline 41% versus placebo in α-Syn-positive participants
- ➤Lecanemab reduced ADAS-Cog14 decline 43% versus placebo in α-Syn-positive participants
- ➤Lecanemab reduced ADCS MCI-ADL decline 43% versus placebo in α-Syn-positive participants
- ➤α-Syn pathology prevalence was 20.4% in Aβ-positive versus 10.0% in Aβ-negative participants
- ➤α-Syn-positive participants had higher baseline amyloid burden, 86 versus 67 Centiloids
Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026 PR Newswire
Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline
Get started
Create a free account to read the full story.
